

4


Docket No. GJE-67
Serial No. 09/856,070Remarks

Claims 31-76 are currently pending in the subject application. By this amendment, claims 31-34 have been amended and claims 35, 37-49 and 67-76 have been canceled. Thus, claims 31-34, 36, and 50-66 are now presented for examination. Also, the applicant has amended the subject claims herein consistent with the election of Group I in order to lend greater clarity to the claimed subject matter and to expedite prosecution. Favorable consideration of the claims is earnestly solicited.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

The Applicants invite the Examiner to call the undersigned if clarification is needed on any aspect of this election and amendment.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Address : 2421 N.W. 41st Street
Suite A-1
Gainesville, FL 32606

DRS/la

Attachment: Marked-up version of amended claims

Marked-up Version of Amended ClaimClaim 31 (amended):

A molecule [that binds to at least one domain of the Heparin Receptor] which is a peptide comprising an amino acid sequence of at least 5 amino acids identical to a portion of amino acids 333-373 of the Heparin Receptor.

Claim 32 (amended):

The molecule, according to claim [1] 31, which comprises [an amino acid sequence which is] a sequence of at least 5 amino acids identical to a portion of amino acids 333-355 of the Heparin Receptor.

Claim 33 (amended):

The molecule, according to claim 32, [which comprises a sequence of] wherein said identical portion is between 5 and 13 amino acids [which is identical to a portion of the Heparin Receptor].

Claim 34 (twice amended):

The molecule, according to claim 32, which comprises an amino acid sequence selected from the group consisting of :

[AREEKHQKQLERQQLETEKKRRETVEREKEQM (SEQ ID NO. 1);]
MREKEELMLRLQDY_(p)EEKTKKAERELSEQIQRALQ (SEQ ID NO. 2);
[TEKKR (SEQ ID NO. 3);
TEKKRRETV (SEQ ID NO. 4);
TEKKRRETVER (SEQ ID NO. 5);
KKRRE (SEQ ID NO. 6);
KKRRETVE (SEQ ID NO. 7);
KKRRETVERE (SEQ ID NO. 8);
KKRRETVEREK (SEQ ID NO. 9);
KKRRETVEREKE (SEQ ID NO. 10);
KRRETVER (SEQ ID NO. 11);
KRRETVEREK (SEQ ID NO. 12);
KRRETVEREKE (SEQ ID NO. 13);

RRETV (SEQ ID NO. 14);
RETVEREKE (SEQ ID NO. 15);]
EREKE (SEQ ID NO. 16);
EREKEQMMREKEEL (SEQ ID NO. 17);
KEELM (SEQ ID NO. 18);
KEELMLRLQDYEE (SEQ ID NO. 19);
KEELMLRLQDYpEE (SEQ ID NO. 20);
EELMLRLQDYEE (SEQ ID NO. 21);
EELMLRLQDYpEE (SEQ ID NO. 22);
ELMLRLQDYEE (SEQ ID NO. 23);
ELMLRLQDYpEE (SEQ ID NO. 24);
MLRLQ (SEQ ID NO. 25);
QDYEE (SEQ ID NO. 26); and
QDYpEE (SEQ ID NO. 27).